PCSK9 Antibody (Rabbit anti human, Polyclonal)

Product Description

PCSK9 Antibody
Catalog number: B2010222
Lot number: Batch Dependent
Expiration Date: Batch dependent
Volume/Weight: 100 uL
pH: na
Supplied as: Ready-to-use
Appearance: Solution
Applications: Rabbit polyclonal antibody specific to human PCSK9. This antibody has been validated in ELISA, FACS, IHC-P, WB.
Storage: -20C
Keywords: anti PCSK9 antibody, anti-PCSK9 antibody
Grade: Biotechnology grade. All components are highly pure (minimum 99%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered on a 0.22 um.

References:
1: Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia.
J Cardiol. 2018 Jan;71(1):1-7.

2: Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of
cardiovascular health. Circ Res. 2014 Mar 14;114(6):1022-36.

3: Wiciński M, Żak J, Malinowski B, Popek G, Grześk G. PCSK9 signaling pathways
and their potential importance in clinical practice. EPMA J. 2017 Aug
14;8(4):391-402.

4: Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation
and in cells. Curr Opin Lipidol. 2014 Oct;25(5):387-93.

5: Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP.
PCSK9 monoclonal antibodies for the primary and secondary prevention of
cardiovascular disease. Cochrane Database Syst Rev. 2017 Apr 28;4(4):CD011748.
doi: 10.1002/14651858.CD011748.pub2. Update in: Cochrane Database Syst Rev. 2020
Oct 20;10:CD011748.

6: Mannarino MR, Sahebkar A, Bianconi V, Serban MC, Banach M, Pirro M. PCSK9 and
neurocognitive function: Should it be still an issue after FOURIER and
EBBINGHAUS results? J Clin Lipidol. 2018 Sep-Oct;12(5):1123-1132.

7: Theocharidou E, Papademetriou M, Reklou A, Sachinidis A, Boutari C, Giouleme
O. The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease
and the Effect of PCSK9 Inhibitors. Curr Pharm Des. 2018;24(31):3654-3657.

8: Paciullo F, Fallarino F, Bianconi V, Mannarino MR, Sahebkar A, Pirro M. PCSK9
at the crossroad of cholesterol metabolism and immune function during
infections. J Cell Physiol. 2017 Sep;232(9):2330-2338.

9: Dixon DL, Trankle C, Buckley L, Parod E, Carbone S, Van Tassell BW, Abbate A.
A review of PCSK9 inhibition and its effects beyond LDL receptors. J Clin
Lipidol. 2016 Sep-Oct;10(5):1073-80.

10: Tsouka AN, Tellis CC, Tselepis AD. Pharmacology of PCSK9 Inhibitors: Current
Status and Future Perspectives. Curr Pharm Des. 2018;24(31):3622-3633.

Products Related to PCSK9 Antibody: Biochemical Buffers and Solutions